Takeda Pharmaceutical Company Limited
TAK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $681,486,000 | $350,008,000 | $385,113,000 | $494,126,000 |
| Short-Term Investments | $58,192,000 | $69,167,000 | $20,476,000 | $32,621,000 |
| Receivables | $702,238,000 | $679,531,000 | $725,254,000 | $735,064,000 |
| Inventory | $1,299,486,000 | $1,240,676,000 | $1,217,349,000 | $1,246,427,000 |
| Other Curr. Assets | $179,218,000 | $173,740,000 | $173,000,000 | $246,049,000 |
| Total Curr. Assets | $2,920,620,000 | $2,513,122,000 | $2,521,192,000 | $2,754,287,000 |
| Property Plant & Equip (Net) | $1,984,126,000 | $1,956,269,000 | $1,968,209,000 | $2,017,776,000 |
| Goodwill | $5,431,698,000 | $5,295,871,000 | $5,324,430,000 | $5,522,112,000 |
| Intangibles | $3,299,225,000 | $3,422,542,000 | $3,631,560,000 | $3,952,039,000 |
| Long-Term Investments | $374,332,000 | $347,120,000 | $361,926,000 | $410,206,000 |
| Tax Assets | $389,768,000 | $401,058,000 | $370,745,000 | $376,264,000 |
| Other NC Assets | $70,531,000 | $68,555,000 | $70,282,000 | $74,158,000 |
| Total NC Assets | $11,549,680,000 | $11,491,415,000 | $11,727,152,000 | $12,352,555,000 |
| Other Assets | $0 | $0 | $0 | $2,000 |
| Total Assets | $14,470,300,000 | $14,004,537,000 | $14,248,344,000 | $15,106,844,000 |
| Liabilities | – | – | – | – |
| Payables | $438,985,000 | $421,308,000 | $308,450,000 | $460,181,000 |
| Short-Term Debt | $293,858,000 | $371,143,000 | $548,939,000 | $135,467,000 |
| Tax Payable | $122,907,000 | $150,965,000 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $1,283,905,000 | $1,226,170,000 | $1,649,132,000 | $1,502,316,000 |
| Total Curr. Liab. | $2,139,655,000 | $2,169,586,000 | $2,506,521,000 | $2,097,964,000 |
| LT Debt | $4,351,462,000 | $4,134,799,000 | $3,966,326,000 | $4,704,681,000 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $33,029,000 | $33,514,000 | $35,153,000 | $37,670,000 |
| Other NC Liab. | $814,465,000 | $800,458,000 | $804,365,000 | $847,338,000 |
| Total NC Liab. | $5,198,956,000 | $4,968,771,000 | $4,805,844,000 | $5,589,689,000 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $7,338,611,000 | $7,138,357,000 | $7,312,365,000 | $7,687,653,000 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1,694,759,000 | $1,694,711,000 | $1,694,685,000 | $1,694,660,000 |
| Retained Earnings | $1,148,658,000 | $1,156,692,000 | $1,187,586,000 | $1,290,948,000 |
| AOCI | -$3,595,000 | $2,347,471,000 | $2,351,915,000 | $2,701,502,000 |
| Other Equity | $4,290,875,000 | $1,666,385,000 | $1,700,898,000 | $1,731,164,000 |
| Total Equity | $7,130,697,000 | $6,865,259,000 | $6,935,084,000 | $7,418,274,000 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $992,000 | $921,000 | $895,000 | $917,000 |
| Total Liab. & Tot. Equity | $14,470,300,000 | $14,004,537,000 | $14,248,344,000 | $15,106,844,000 |
| Net Debt | $3,963,834,000 | $4,155,934,000 | $4,130,152,000 | $4,346,022,000 |